正大企業國際：2022中期報告.pdf

1、INTERIM REPORT 2022 中期報告CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正 大 企 業 國 際 有 限 公 司Incorporated in Bermuda with limited liability Stock Code:3839於 百 慕 達 註 冊 成 立 之 有 限 公 司 股份代號:383901IN T ERIM REP OR T 2022二 零 二 二 年 中 期 報 告正 大 企 業 國 際 有 限 公 司 CHIA TAI ENTERPRISES INTERNATIONAL LIMITED2Management D

2、iscussion and Analysis管理層討論及分析6Report on Review of Interim Financial Report中期財務報告之審閱報告8Consolidated Statement of Comprehensive Income綜合全面收益表10Consolidated Statement of Financial Position綜合財務狀況表12Consolidated Statement of Changes in Equity綜合權益變動表14Condensed Consolidated Statement of Cash Flows簡明綜合現金流

3、量表15Notes to Interim Financial Report中期財務報告附註31Other Information其他資料35Corporate Information公司資料 Contents目 錄02IN T ERIM REP OR T 2022二 零 二 二 年 中 期 報 告正 大 企 業 國 際 有 限 公 司 CHIA TAI ENTERPRISES INTERNATIONAL LIMITEDGROUP RESULTSChia Tai Enterprises International Limited(the“Company”)and its subsidiaries

4、(the“Group”)have two lines of business:biochemical business and industrial business.The biochemical business focuses on chlortetracycline(“CTC”)and other related products,and is carried on by Group subsidiaries.This business segment accounts for all of the Groups consolidated revenue.The industrial

5、business comprises the Groups interests in its joint venture ECI Metro Investment Co.,Ltd.(together with its subsidiaries,“ECI Metro”)and its associate Zhanjiang Deni Vehicle Parts Co.,Ltd.(together with its subsidiaries,“Zhanjiang Deni”).The results of the Groups industrial business are incorporate

6、d in the consolidated statement of comprehensive income as share of profits and losses of joint venture and associate.For the six months ended 30 June 2022(“1H22”),the Groups revenue increased by 28.2%to US$81.21 million(for the six months ended 30 June 2021(“1H21”):US$63.37 million).Overall,gross p